Antisense hammerhead ribozymes have the capability to cleave complementary RNA in a sequence-dependent manner. In osteogenesis imperfecta, a genetic disorder of connective tissue, mutant collagen type I has been shown to participate in but not sustain formation of the triple helix. Selective ablation of mutant collagen gene transcript could potentially remove the mutant gene product and reverse the dominant-negative effect exerted by the abnormal protein. In earlier studies we showed that the hammerhead ribozyme Col1A1Rz547 selectively cleaved a mutant Col1A1 gene transcript in a murine calvarial osteobleast cell line. In order to test the possible therapeutic efficacy of this approach, a dramatic downregulation of the mutant transcript must be achieved, a function directly related to high steady-state level of intracellular ribozyme. We report significantly enhanced expression of Col1A1Rz547 by vaccinia T7 polymerase following infection with an attenuated T7-pol vaccinia virus as shown both by the intracellular level of the ribozyme and the cleavage of the mutant Col1A1 gene transcript. We also describe the engineering of a multimeric ribozyme construct comprising eight subunits, which can self-cleave to monomers. These studies suggest the potential use of multimeric ribozymes expressed by a vaccinia-based system in the therapy of a variety of disorders.
Introduction
The application of nucleic acids as antisense reagents for the downregulation of expression of disease causing genes has been the focus of a great deal of attention for more than 20 years. 1, 2 Hammerhead ribozymes are small RNA molecules with a catalytic core of less than 40 nucleotides (nt) that can be resolved into a substrate and a catalytic strand. [3] [4] [5] [6] [7] It is possible that any RNA molecule can be cleaved by hammerhead ribozymes in trans, provided it contains a putative cleavage site. These ribozymes have been applied to downregulate a variety of genes, and their potential as therapeutic agents in the management of genetic disorders, particularly those whose pathogenesis is the result of a dominant-negative effect exerted by a mutant gene product, has been widely recognized. [8] [9] [10] [11] More recently, the discovery of the role of RNA interference (RNAi) in post-transcriptional gene silencing has led to the suggestion that a new class of RNA-based therapeutics might be developed. [12] [13] [14] Unlike the antisense and RNAi approaches, which both rely on the action of the cellular machinery for their effect, hammerhead ribozymes act directly to cleave their target mRNA. Additionally, hammerhead ribozymes have the advantage of being able to discriminate between closely related target RNAs, even when the two RNA species differ by as little as a single nucleotide. 15 Selective intracellular ablation is a strategy particularly suited to conditions like osteogenesis imperfecta (OI), a systemic disorder of connective tissue presenting with osseous fragility, short stature, hearing loss, dental defects, and blue sclerae. 16, 17 Mutations in either of the genes encoding the proa1(I) and proa2(I) chains of collagen type I have been identified in many affected individuals, and have been determined to be the underlying cause of OI. 16 Several studies on the molecular pathology of OI have identified two mechanisms of collagen type I defects. 16 In one, null mutations result in the synthesis of mutant collagen chains that cannot be incorporated in the collagen triple helix. This mechanism leads to the deposition of half normal levels of collagen type I in the extracellular matrix and is associated with a mild clinical phenotype. 18 The second mechanism results from the incorporation of mutant protein into the collagen triple helix, thus disrupting the collagen fibrillar structure. These dominant-negative mutations are associated with phenotypes ranging in severity from moderate to lethal. 16 Several murine models of OI have been described. [19] [20] [21] [22] Pereira et al 23 generated mice transgenic for an internally deleted human gene for the proa1(I) chain of collagen type I. The deleted minigene (pMG155) was designed to synthesize shortened proa1(I) chain which could participate in but not sustain the formation of the triple helix, thus depleting the endogenous procollagen type I through protein suicide. 23, 24 Wenstrup et al 25 developed MC3T3-E1, a murine calvarial osteoblast cell line stably expressing pMG155 that has been used as a model system to study the effect of dominant-negative OI mutations.
We previously tested the use of an antisense ribozyme complementary to a particular sequence of the human mutant minigene target, pMG155, abundantly expressed in MC3T3-E1 cells. After intracellular delivery of a ribozyme expression construct, intracellular ribozyme transcript was detected along with a relative reduction of pMG155 mutant collagen transcript level. 26 Thus, the ribozyme was shown to be biologically active and its potential value in the therapy of OI was demonstrated. However, the utility of this monomeric ribozyme was limited by the restrictions of the transient expression system used. Previous studies have established that even a small fraction of mutant protein is sufficient to produce a clinically severe OI phenotype. 19 Therefore, in order to achieve a therapeutic effect, a dramatic downregulation of the mutant transcript might be necessary. This could be accomplished by increasing the level of ribozyme available intracellularly. We report here on two alternate yet complementary modalities aimed at achieving higher intracellular ribozyme availability: firstly, a multimeric ribozyme construct that produces a single transcriptional unit containing multiple copies of the ribozyme motif and capable of self-cleavage; 27 secondly, infection with a modified vaccinia virus Ankara (MVA) that produces large quantities of recombinant T7 polymerase, which acts on T7 promoter bearing ribozyme sequence to achieve rapidly a high level of ribozyme transcript. 28 
Results
The octameric ribozyme cleaves both in cis and trans
In vitro transcription of the octameric transcript demonstrated that the transcript efficiently underwent ciscleavage to produce the monomeric subunit.
Transcription was carried out in the presence of 8 mM MgCl 2 to minimize cis-cleavage during the transcription reaction, and synthesized transcript was subsequently incubated in 20 mM MgCl 2 to assay for cis-cleavage activity. A ladder of fragments of between 70 and B500 nt, the sizes expected if the octameric transcript were to cis-cleave (Figure 1b) , was observed following in vitro transcription. Subsequent incubation in the presence of the higher MgCl 2 concentration led to accumulation of the 70 nt monomeric subunit (Figure 1c ). Incubation at 501C resulted in increased cleavage as compared to 371C, as has been observed previously for hammerhead ribozymes. 8 In addition, the octameric ribozyme was able to cleave its target sequence in trans. Incubation of a 205 nt minigene target transcript with octameric ribozyme transcript led to accumulation of increasing amounts of the 130 and 75 nt subfragments expected if the ribozyme cleaved its putative cleavage site over time (Figure 1d ). The MVA-T7 recombinant virus was used to achieve high level of ribozyme expression from the T7 promoter in minigene-expressing MC3T3-E1 cells. Cells were infected with crude virus stocks following transfection with plasmid constructs designed to express the Col1A1Rz547 ribozyme from the T7 promoter. RNase protection analysis (RPA) of lysates from cells expressing the original monomeric Col1A1Rz547 ribozyme using the MVA-T7 system showed a substantial reduction in the amount of minigene transcript relative to control cyclophilin transcript compared to cells transfected with vector alone (Figure 2a ). In addition, an 80 nt protected subfragment (MGCF), the expected result of minigene cleavage by the ribozyme, appears only in cells expressing the monomeric ribozyme ( Figure  2a ).
Western blot analysis of cell lysates showed that the level of the truncated collagen encoded by the minigene is also reduced in MVA-T7-infected cells transfected with ribozyme construct compared with cells transfected with vector alone (Figure 2b ). In contrast, the expression of the ribozyme did not affect the endogenous collagen protein.
Surprisingly, RPA of cells transfected with the octameric ribozyme construct showed little reduction in the amount of minigene transcript ( Figure 2a ).
Efficacy of Col1A1Rz547 in cultured cells is dependent on ribozyme structure and survival
The unexpected finding that the octameric ribozyme construct was less effective than the original monomeric Col1A1Rz547 construct when delivered to cultured cells led us to investigate the intracellular concentration of ribozyme produced by these constructs. RPA of lysates from cells transfected with monomeric or octameric ribozyme construct was performed using either monomeric or octameric ribozyme riboprobe (Figure 3a We hypothesize that the downstream vector sequence protects the monomeric ribozyme transcript from exonuclease degradation, while the octamer, following selfcleavage into the R1 subunits that lack any protective 3 0 sequence, is rapidly degraded by RNases. Supporting this hypothesis is the decreasing intensity of the protected octamer probe by the cellular octamer RNA, as its size decreases (Figure 3b -R8) . (a) RPA of lysate from minigene-expressing cells transfected with ribozyme constructs. Lanes 1 and 2, RPA of cells transfected with vector alone using minigene or control cyclophilin riboprobe, respectively. Lanes V, Rz, and R8, RPA of cells transfected with vector, monomeric ribozymes, or octameric ribozymes respectively, using both minigene and cyclophilin riboprobes. Lane P contains full-length minigene (m) and cyclophilin (c) riboprobes. The position of the protected minigene and cyclophilin fragments, as well as endogenous collagen and the minigene cleavage fragment (MGCF), is shown on the left. The protected minigene fragment is detected as a doublet. (b) Western blot analysis of cell lysates using the LF41 antibody that recognizes both native murine col1A1 and the truncated collagen encoded by the minigene. Lane C, minigene-expressing cells. Lane F6, control cells that do not express the minigene. Lanes V and Rz, minigene-expressing cells transfected with vector or ribozyme construct, respectively. The position of mouse col1A1 and the truncated collagen encoded by the minigene is indicated on the left.
Ablation of
This would predict that the level of intracellular ribozyme following transfection with a construct expressing the monomeric subunit of the octamer construct (R1) would be similar to that following transfection with the octameric construct. This level would be expected to be lower than that produced by transfection with the monomeric ribozyme Rz construct that lacks cis-cleavage activity. The level of the target minigene transcript would be expected to mirror the concentration of the intracellular ribozyme.
The data presented in Figure 4 demonstrate this to be the case. RPA of cells transfected with the original monomeric ribozyme construct showed a significantly higher level of intracellular ribozyme than that observed following transfection with either the cis/trans monomeric subunit or the octamer (Figure 4a , lanes Rz, R1, and R8, respectively). This is reflected in the level of minigene transcript detected (Figure 4b , lanes Rz, R1, and R8) and the appearance of minigene cleavage product (Figure 4b -MGCF) .
The difference in efficacy between the monomeric ribozyme Rz and both the R1 subunit and octamer correlates with the length of 3 0 sequence present. This length difference is due to the cis-cleaving activity incorporated into the latter two molecules. Given this difference, we decided to directly test the effect of the length of 3 0 sequence on intracellular ribozyme concentration and efficacy. Transfection with a series of constructs designed to produce transcripts with different lengths of sequence 3 0 to the ribozyme motif was investigated with respect to the subsequent concentration of both intracellular ribozyme and minigene transcript. The plasmid expressing the Col1A1Rz547 ribozyme was linearized at several sites for the production of transcripts that differ solely in the presence of vector-encoded sequence 3 0 to the ribozyme motif that vary in length from 0 to 2150 bases in length. We also used the original circular plasmid construct that produces a ribozyme transcript with a 3 0 extension longer than 3050 bases (see above). RPA of total RNA from cells transfected with these constructs, using minigene-and ribozyme-specific riboprobes, demonstrated that intracellular ribozyme survival and concomitant reduction in target minigene transcript were dependent on the length of 3 0 vector transcript length ( Figure 5 ).
Discussion
We have established the transient expression of hammerhead ribozymes in the murine calvarial osteoblast line MC3T3-E1 as a model system to investigate their biological effect in downregulating the expression of the pMG155 minigene. We previously showed that the hammerhead ribozyme Col1A1Rz547, engineered to specifically cleave the sequence of the minigene target, was indeed able to cleave the target in vitro and in cellulo. 26 However, in order to achieve substantive response, we needed to significantly increase the steadystate level of intracellular ribozyme.
The first approach was to synthesize a multimeric ribozyme, capable of self-cleaving into monomeric units, thus producing multiple ribozyme molecules per transcript. Transcription of a longer transcript is more efficient because reassembly of the transcriptional initiation machinery is a rate-limiting factor. The octameric ribozyme was shown to be capable of selfcleavage and of cleaving its intended target in the test tube.
The second approach was the use of the vaccinia/T7 polymerase system to express high levels of ribozyme. This polymerase is more efficient than eucaryotic RNA polymerases and can act in trans on T7 promoter bearing target sequences to achieve rapidly a high level of cytoplasmic gene expression. This system has been used successfully to express transiently high levels of a number of proteins and viral RNAs in cultured cells. Our data demonstrated significant decrease of mutant minigene transcript and of the corresponding mutant protein, consistent with previous observations following transfection with the trans-acting ribozymes. 8, 28 We decided to adopt this approach as a model system for the initial testing of ribozymes in cellulo to select those appropriate for stable expression.
We assumed that expression of the octamer by the vaccinia/T7 polymerase would offer an added advantage. To our surprise, expression of the octameric ribozyme did not reduce the level of the minigene target. RPA analysis revealed that the T7 polymerase continues transcription around the plasmid in a 'rolling circle' manner, as previously reported. 29 We reasoned that the resultant downstream vector transcript sequence protects the ribozyme from cellular RNases, thus increasing its level in the cell. In contrast, the octamer ribozyme transcript undergoes cis-cleavage rendering the individual ribozyme motifs susceptible to RNase degradation. For this reason, the ribozyme level in cells transfected with the octamer was significantly lower compared to cells transfected with the original monomer. We assumed that for the same reason, the monomeric subunit would be equally susceptible to degradation, which proved to be true. Our hypothesis was further substantiated by the demonstration that both ribozyme level and consequent target cleavage were dependent on the length of downstream vector tail. 
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Based on these data, it may be possible to define an optimal length and sequence of 3 0 transcript for maximal cell survival and target cleavage. Furthermore, the insertion of a T7 termination signal into the appropriate position 3 0 to the ribozyme motif might allow transcription of a ribozyme with optimal tail size from a circular plasmid. Alternative approach would be to utilize short sequences known to stabilize mRNAs. 30 We have used the vaccinia/T7 polymerase system for transient expression studies. As the MVA strain does not usually replicate mammalian cells, we envision infection-transfection to be repeatable, thus prolonging ribozyme expression. Vaccinia virus has long been used for vaccination, and the mild reactions and side effects associated with its administration are well documented. 31 This suggests that vaccinia could be used safely for gene therapy. [31] [32] [33] Unlike retroviral vectors, vaccinia allows the transcription of genes with a polyadenylation signal, which improves transcript stability. 34 An additional advantage is the cytoplasmic localization and lack of integration into the host genome. 31, 32, 34 Large genomic deletions represent only a small fraction of OI mutations observed in the human, where the great majority are point mutations in a glycine codon. 16 Glycine substitutions have been detected throughout the entire triple helical domain and have been associated with phenotypes ranging from mild to neonatal lethal. The lack of reduction of the endogenous murine collagen type I is in agreement with our earlier observations on the specificity of the ribozyme for its target.
14 This feature could prove particularly useful in targeting sequences that are present in multiple copies as in the glycine residues of the triple helical domain of collagen type I.
Materials and methods

Plasmid and virus preparation
The construction of the minigene-and the Col1A1Rz547 ribozyme (Rz)-expressing vectors pGEM-T/547 and pGEM-T/Rz was previously described. 26 The octameric ribozyme construct was synthesized by multimerization of a monomeric subunit comprising the ribozyme target sequence for cis-cleavage alongside the ribozyme sequence for trans-cleavage (Figure 1a) . 27 The cis-transmonomeric subunit (R1) flanked by HindIII and XbaI sticky ends was generated by annealing the two oligodeoxynucleotides shown in Figure 1b . The monomer was ligated into the HindIII and XbaI sites of pBluescript SK þ (Stratagene, La Jolla, CA, USA) to yield the pBS-RZII plasmid. The monomeric subunit was excised from pBS-RZII using SpeI and XbaI enzymes, and ligated back into the vector in the reverse orientation to generate pBS-T7-Rzc, which was used to express the monomeric subunit.
The strategy used to produce tandem repeats of the monomeric subunit was based on the use of the restriction enzymes Xba I and Spe I that produce compatible sticky ends. Fragments produced by crossligation of Xba I-Spe I sticky ends are resistant to digestion by both enzymes, and thus successive ligation and digestion reactions produce fragments containing tandem repeats of the ribozyme fragment of known directionality. The monomeric subunit flanked by Xba I-Spe I restriction sites was self-ligated using T4 DNA ligase, a second Xba I-Spe I digestion performed, and the resulting fragments separated on an agarose gel. The band containing eight copies of the ribozyme was purified and ligated into Xba I-digested pBS547Rz to produce pBS-oct8.2 containing eight copies of the monomeric subunit sequence) (Figure 1b) . To prevent deletion of rearrangements of the multimers, clones were propagated in the SURE strain (Stratagene, La Jolla, CA, USA).
The octamer was excised from pBS-oct8.2 using NotI and HindIII, and ligated into pcDNA3.1/Zeo(À) to generate pD3Rz8mer for expression of the octamer in cultured cells. For expression of ribozymes with defined length of downstream vector sequence, pGEM-T/Rz was digested with NotI, PvuII, ApaLI, AvaII, or SspI, for generation of ribozyme transcripts with 0, 270, 760, 1480, or 2200 bases of downstream vector sequence, respectively.
The modified vaccinia virus Ankara expressing recombinant bacteriophage T7 polymerase (MVA-T7) was grown in BHK-21 cells as previously described 35 for preparation of crude stocks.
Cell culture and infection-transfection of cells
The mouse calvarial cells MC3T3-E1 were maintained as described. 25 For RPA, cells were plated on 100 mm plates at a concentration of 1.5 million cells/plate 24 h prior to infection-transfection. For Western analysis (WA), cells were plated in 35 mm wells at a concentration of 250 000 cells/well. Cells were washed with PBS and incubated for 1 h in 20 ml (WA-5 ml) of crude MVA-T7 (2 Â 10 8 CFU/ml) preparation in 3 ml (WA-0.8 ml) of OptiMEM medium (Gibco, Carlsbad, CA, USA). A volume of 30 mg (WA-5 mg) of plasmid and 60 ml (WA-10 ml) Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in 3 ml (WA-0.8 ml) medium were added and cells incubated for an additional 4-6 h (WA-13 h). For RPA, cells were washed with PBS, detached by trypsin-EDTA (Gibco, Carlsbad, CA, USA) treatment, collected in growth medium, centrifuged, and lysed in Lysis/ De-naturation Solution (Ambion, Austin, TX, USA) (15 000 cells/ml). For WA, cells were lysed, dialyzed, and lyophilized as described. 25 In vitro transcription and ribozyme cleavage Antisense minigene riboprobe was transcribed from pGEM-T/547 following linearization by NcoI. Ribozyme probe was transcribed from pGEM-T/Rz following digestion with PvuII (see Figure 5b) , and cyclophilin probe was transcribed from pTRI-Cyclophilin (Ambion, Austin, TX, USA). Transcription reactions were performed using 50 mCi a-32 P-UTP (800 ci/mmol) (PerkinElmer, Boston, MA, USA), ATP, CTP, GTP (MBI, Hanover, MD, USA), and SP6 RNA polymerase (Invitrogen, Carlsbad, CA, USA) following manufacturers' specifications. The octamer probe and the 205 base radiolabeled minigene target RNA were transcribed from a 765 bp PCR fragment generated from pBSoct8.2 using M13LacZ forward and reverse primers (Perkin-Elmer, Boston, MA, USA) and pGEM-T/547 using T7 RNA polymerase (Invitrogen, Carlsbad, CA, USA). Probes were purified either by a 6% denaturing PAGE or by NucAway spin columns (Ambion, Austin, TX, USA). Large-scale in vitro transcription of octamer ribozyme was carried out as described. 26 Ribozyme cleavage reactions were carried out in a total volume of 30 ml in 50 mM Tris-HCl pH 7.5 and 20 mM MgCl 2 for 0-120 min and were terminated by addition of 1 ml of 0.5 M EDTA.
RNase protection assays
RPA was carried out using Direct Protect Lysate RPA kit (Ambion, Austin, TX, USA). Lysates of 300 000 cells were hybridized with 200 000 cpm of the appropriate riboprobes for 2 h. Hybridization was at 551C for minigene riboprobe or 531C for ribozyme riboprobes. Following hybridization, digestion with RNase cocktail was for 4 h at 371C. Protected fragments were analyzed on denaturing PAGE and quantified as described. 26 
Western analysis
The minigene protein and endogenous proa1(I) collagen were detected by WA essentially as described previously. 25 . Briefly, samples were dialyzed against 0.5 M acetic acid and lyophilized. Proteins were then separated by electrophoresis on SDS-PAGE gels, and electroblotted onto polyvinyldifluoride membranes (Osmonics Inc., Minnetonka, MN, USA). The membranes were reacted with polyclonal antisera to a peptide sequence from the carboxyl-propeptide of human proa1(I) sequence (LF41).
